Shenzhen Salubris Pharmaceuticals

Overview

Compare with another stock.

• Ticker002294 on Shenzhen Stock Exchange¹

See how the biggest companies compare on our leaderboards

Shenzhen Salubris Pharmaceuticals (Chinese: 深圳信立泰药业; pinyin: Shēnzhèn Xìnlìtài Yàoyè; SZSE: 002294) is a Chinese pharmaceutical company.²

Calendar

Drug trials and FDA: coming up

1. Dec 12, 2026Phase 2 trial readout expected Phase 2 trial of SAL0137 Dose 1, SAL0137 Dose 2 and others in Elevated Lipoprotein(a): primary completion expected Dec 12, 2026 (ClinicalTrials.gov NCT07729475).³
2. Mar 1, 2027Phase 2 trial readout expected Phase 2 trial of SAL0140 in Uncontrolled Hypertension: primary completion expected Mar 1, 2027 (ClinicalTrials.gov NCT07654140).⁴
3. Apr 1, 2027Phase 2 trial readout expected Phase 2 trial of SAL0140 Tablets in Primary Aldosteronism: primary completion expected Apr 1, 2027 (ClinicalTrials.gov NCT07646535).⁵
4. Jun 2027Phase 4 trial readout expected Phase 4 trial of Enarodustat 2mg, Enarodustat 3mg and others in Renal Anemia in Non-dialysis Chronic Kidney Disease: primary completion expected Jun 2027 (ClinicalTrials.gov NCT07079579).⁶
5. Oct 8, 2027Phase 2 trial readout expected Phase 2 trial of SAL0140 Tablets in Chronic Kidney Disease: primary completion expected Oct 8, 2027 (ClinicalTrials.gov NCT07647133).⁷
6. Oct 2027Phase 2 trial readout expected Phase 2 trial of GW906 in Hypertension: primary completion expected Oct 2027 (ClinicalTrials.gov NCT07835984).⁸

Drug trials and FDA: recently

1. Sep 15, 2026Phase 2 trial completed Phase 2 trial of GW906 in Hypertension: primary completion Sep 15, 2026, no results posted yet (ClinicalTrials.gov NCT07835971).⁹
2. Jul 2, 2026Phase 3 trial completed Phase 3 trial of SAL0120 in Uncontrolled Hypertension: primary completion Jul 2, 2026, no results posted yet (ClinicalTrials.gov NCT07790120).¹⁰
3. Nov 10, 2025Phase 3 trial completed Phase 3 trial of Experimental: Sacubitril/Allisartan and Amlodipine Group and Active Comparator: Sacubitril/Allisartan Group in Essential Hypertension: primary completion Nov 10, 2025, no results posted yet (ClinicalTrials.gov NCT07704697).¹¹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Links

• WikipediaSalubris Pharmaceuticals
• WikidataQ20716869